PRJNA432413
Optimized ARID1A immunohistochemistry is an accurate predictor of  ARID1A mutational status in gynaecological cancers (MiSeq)
ARID1A is highly mutated in clear cell and endometrioid carcinomas of the ovary and endometrium. We have optimised and validated ARID1A IHC as a useful biomarker to stratify gynaecological cancer patients with 100% accuracy.